PROMO!
First order? Get 10% OFF with this code: 1storder
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a synthetic analogue of the purine nucleoside and a compound used in metabolic research which, when phosphorylated inside cells, produces ZMP, an AMP analogue that has been studied in experiments with regard to its interactions on AMP-sensitive cellular signaling pathways.
AICAR, also known as 5-aminoimidazole-4-carboxamide ribonucleotide or acadesine, is a synthetic nucleoside analogue and adenosine monophosphate (AMP) mimetic widely utilized in experimental research. Unlike peptides or peptide analogues, AICAR is a low-molecular-weight small molecule that functions as a biochemical tool for investigating cellular energy metabolism and nucleotide-associated signaling pathways. Once transported into cells, AICAR is phosphorylated to form 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP), an intermediate of the de novo purine biosynthesis pathway that has been extensively characterized in biochemical studies.
Originally developed as part of research into purine metabolism, AICAR has become recognized as a valuable experimental compound for investigating AMP-activated protein kinase (AMPK) signaling and associated metabolic processes. Its well-defined chemical structure and established intracellular metabolism have made it a widely used reagent in cell culture experiments, enzymatic assays and preclinical research models examining cellular responses to altered energy status.
Since AICAR (5-aminoimidazole-4-carboxamide ribonucleotide precursor), commonly referred to as acadesine, is a synthetic nucleoside analogue, it lacks a higher-order peptide structure and a fundamental amino acid sequence. AICAR is a low-molecular-weight chemical molecule made up of an aminoimidazole carboxamide moiety connected to a ribose sugar, in contrast to peptides and recombinant proteins. It is a valuable study drug for biochemical studies because of its compact molecular structure, which closely mirrors naturally occurring purine biosynthesis intermediates.
As a small polar molecule, AICAR exhibits high aqueous solubility and is readily prepared in aqueous laboratory buffers for use in biochemical and cell culture experiments. The presence of multiple hydrogen bond donors and acceptors, together with hydroxyl groups on the ribose ring, contributes to its hydrophilic character and relatively low hydrophobicity. Under physiological conditions, the molecule is largely uncharged, although its ionisation state may vary slightly depending on pH.
Unlike peptide-based research compounds, AICAR does not contain secondary or tertiary structural elements and is not subject to peptide-specific modifications such as amidation, cyclisation or disulphide bond formation. Storage conditions, including temperature, moisture and prolonged exposure to light, influence its chemical stability. When handled according to recommended laboratory practices, the compound demonstrates suitable stability for experimental use. Identity, purity and structural integrity are routinely verified using high-performance liquid chromatography (HPLC), liquid chromatography–mass spectrometry (LC-MS) and, where appropriate, nuclear magnetic resonance (NMR) spectroscopy.
AICAR is a synthetic adenosine analogue that is transported intracellularly and then phosphorylated by adenosine kinase to create 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP), according to recent laboratory studies. ZMP is an AMP mimic that has been thoroughly studied for its interaction with AMP-sensitive signaling pathways involved in cellular energy balance, according to published experimental research. The main method used in biochemical and molecular biology research to characterize AICAR is this intracellular conversion.
In vitro models have explored the interaction of ZMP with AMP-activated protein kinase (AMPK), a serine/threonine kinase that acts as a regulator of cellular energy sensing. Structural and biochemical studies have examined the binding of ZMP to the γ-subunit of AMPK, where it has been characterised as influencing conformational changes associated with kinase activation. These investigations have employed enzyme kinetics, crystallographic studies and cell-based assays to characterise the molecular interactions between ZMP and the AMPK complex.
Published research has further examined downstream signalling pathways associated with AMPK following intracellular conversion of AICAR. Experimental studies have characterised phosphorylation events involving targets such as acetyl-CoA carboxylase (ACC), mammalian target of rapamycin (mTOR)-associated signaling components, and transcriptional regulators including peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α). These investigations have focused on defining intracellular signaling networks and molecular responses under controlled laboratory conditions rather than establishing physiological outcomes.
Current laboratory investigations have also examined the role of AICAR in purine metabolism because ZMP is an intermediate within the de novo purine biosynthesis pathway. Metabolomic analyses, isotope-tracing experiments and biochemical assays have been utilized to characterize nucleotide metabolism, intracellular transport and enzymatic flux associated with AICAR metabolism. The mechanism of AICAR therefore continues to be investigated through biochemical, structural biology and preclinical research, with published evidence characterizing its principal molecular activity as intracellular conversion to ZMP and subsequent interaction with AMPK-regulated signaling pathways.
The summary is based upon findings that have been recorded in the published preclinical and in vitro literature, the main studies being listed in the reference section.
Cellular metabolism represents one of the principal areas in which AICAR has been investigated. Published studies have utilized cultured cell systems to examine intracellular energy sensing, nucleotide metabolism and biochemical responses following the intracellular conversion of AICAR to ZMP. Experimental models have employed metabolomic analyses and biochemical assays to characterize metabolic pathways under controlled laboratory conditions.
Molecular biology research has examined AICAR using techniques such as quantitative PCR, Western blotting, RNA sequencing, and transcriptomic profiling to investigate gene and protein expression associated with AMP-responsive signaling pathways. These approaches have been used to characterize molecular responses and intracellular regulatory networks in a variety of experimental systems.
AICAR has been extensively investigated as a research tool for studying intracellular signal transduction. Published experimental studies have examined AMP-activated protein kinase (AMPK) signaling together with downstream kinase activity, phosphorylation events and transcriptional regulation. Laboratory investigations have utilized biochemical assays and molecular analyses to characterize signaling pathways associated with cellular energy sensing.
Experimental enzymology studies have investigated the metabolism of AICAR and its conversion to ZMP by adenosine kinase. Research has also examined enzyme kinetics, substrate recognition, and interactions with enzymes involved in purine biosynthesis and nucleotide metabolism. These investigations have contributed to the characterization of intracellular metabolic pathways at the enzymatic level.
Biochemical research has utilized AICAR to investigate nucleotide metabolism, cellular bioenergetics and AMP-responsive molecular pathways. Experimental methodologies have included enzyme activity assays, metabolite quantification, isotope-tracing experiments, and phosphoproteomic analyses to characterize intracellular biochemical processes in vitro and in preclinical models.
The pharmacokinetic and pharmacodynamic properties of AICAR have been investigated in preclinical pharmacology research using lab models. Published studies have used biochemical assays and analytical techniques intended to assess the drug under well regulated experimental settings to characterize cellular uptake, intracellular conversion, tissue distribution, and metabolic destiny.
AICAR is a synthetic small molecule and is not manufactured using Solid Phase Peptide Synthesis (SPPS). It is produced through organic synthesis, followed by purification and analytical quality control to verify chemical identity, purity and batch consistency.
To get rid of leftover starting materials, reaction byproducts, and other process-related contaminants, the AICAR molecule is frequently processed using chromatographic procedures after synthesis. To measure the AICAR chemical purity and evaluate batch uniformity, high-performance liquid chromatography (HPLC) is frequently utilized. The expected molecular mass and compound identity are confirmed using liquid chromatography–mass spectrometry (LC–MS).
Every production batch is subjected to analytical verification as part of standard quality control procedures before being released for research use. In order to facilitate laboratory research applications, batch-specific test results are documented in a Certificate of Analysis (CoA), which usually includes compound identity, analytical purity, molecular mass confirmation, and batch identification.
In order to preserve its stability during storage and transportation, AICAR is frequently given as a lyophilized powder. In order to prevent hydrolytic deterioration and preserve the compound until it is ready for laboratory use, the freeze-drying procedure eliminates water from the substance.
The lyophilized material should be stored for an extended period of time in a refrigerator between 2 and 8°C, or as directed by the manufacturer. When not in use, the container should be kept well sealed to reduce exposure to air moisture because extended dampness can eventually degrade the dry material's quality.
AICAR should also be shielded from prolonged exposure to intense heat and direct light to preserve chemical integrity. Limiting unnecessary air exposure during handling is considered good laboratory practice, even though the drug is stable under suitable storage conditions.
The lyophilized powder should be reconstituted using the sterile laboratory diluent suggested by the manufacturer before being used in an experiment. After the solution is ready, it should be used within the suggested time frame and kept in the refrigerator.
Indeed. AICAR is sometimes referred to as an analogue of adenosine monophosphate (AMP), or more accurately, an AMP mimetic. Adenosine kinase phosphorylates it after cellular absorption to produce 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP), a purine biosynthesis step that shares structural similarities with AMP. In research on AMP-responsive signaling pathways, this intracellular metabolite—rather than AICAR itself—has been thoroughly studied.
Although AICAR and AMP share structural similarities, they are distinct molecules with different biochemical origins. AMP is a naturally occurring nucleotide involved in cellular energy metabolism, whereas AICAR is a synthetic nucleoside analogue that requires intracellular phosphorylation to form ZMP. Published studies have characterized ZMP as an AMP mimetic that has been investigated for its interaction with AMP-sensitive enzymes and signaling pathways.
The principal enzyme involved in AICAR metabolism is adenosine kinase, which phosphorylates AICAR to produce ZMP. Once formed, ZMP participates in biochemical pathways associated with de novo purine biosynthesis and has been examined in relation to enzymes involved in nucleotide metabolism. Experimental studies have utilized enzymatic assays and metabolomic analyses to characterize these intracellular metabolic processes.
Yes. Published research has demonstrated that AICAR is transported across the plasma membrane before undergoing intracellular phosphorylation. Cellular uptake has been characterized as occurring through nucleoside transport systems, enabling the compound to enter a variety of cultured cell types used in experimental research. Intracellular conversion to ZMP follows uptake into the cytosol.
According to experimental research, equilibrative nucleoside transporters (ENTs), which enable the bidirectional passage of nucleosides across the plasma membrane, are principally responsible for the transportation of AICAR into cells. Adenosine kinase quickly phosphorylates AICAR once it enters the cell, hence preserving the intracellular concentration gradient that promotes ongoing uptake. Biochemical investigations and cell-based transport tests have been used to characterize these transport processes.
Published investigations have examined several transcriptional regulators following intracellular conversion of AICAR to ZMP and subsequent activation of AMP-responsive signaling pathways. Experimental studies have characterized the involvement of transcription factors and co-regulators including peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), forkhead box O (FOXO) proteins and cAMP response element-binding protein (CREB), together with additional downstream transcriptional networks. These investigations have focused on defining molecular signaling responses in cell culture and preclinical models.
The relationship between AICAR and AMP-activated protein kinase (AMPK) signaling has been extensively characterized in the scientific literature. Following intracellular phosphorylation to ZMP, the metabolite has been investigated for its interaction with the γ-subunit of the AMPK complex, where it functions as an AMP mimetic. This interaction has been examined using biochemical assays, structural biology and cell-based models to investigate AMPK-regulated signaling pathways and associated intracellular phosphorylation events.
The information presented on this page is provided for scientific and educational purposes only and summarises the current published literature relating to AICAR (5-aminoimidazole-4-carboxamide ribonucleoside). The content is intended to describe the compound’s chemical identity, molecular characteristics, analytical verification and experimental research context. References to adenosine monophosphate (AMP) analogues, AMP-activated protein kinase (AMPK) signalling, purine metabolism and intracellular biochemical pathways are based on findings from biochemical studies, cell-based assays and preclinical research models and should be interpreted solely within that experimental context.
AICAR is supplied exclusively as a research material and is not intended for human or veterinary use. It is not approved for use in the treatment, cure or prevention of any disease. Descriptions of molecular mechanisms, enzyme interactions or intracellular signaling pathways do not constitute evidence of clinical efficacy, physiological effects or therapeutic application.
Researchers are responsible for ensuring that AICAR is handled, stored and utilized in accordance with recognized laboratory practices, institutional guidelines and all applicable regulations. Experimental procedures should be conducted only by appropriately qualified personnel using validated laboratory methods, appropriate safety controls and documented quality assurance practices.
